Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSN084 in advanced malignant tumors
NCT05300438Phase 1Active, not recruiting
- Sponsor
- Tyligand Bioscience
- Start
- Feb 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TSN084 in cancer, sponsored by Tyligand Bioscience. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events. Started Feb 2022; status: active, not recruiting.
02
Drugs
TSN084
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05300438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300438.